Insights on adjuvant endocrine therpay for premenopausal and postmenopausal breast cancer

Expert Review of Anticancer Therapy

Volumn 7, Issue 9, 2007, Pages 1243-1253

  Briest, Susanne ^a,b   Wolff, Antonio C ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Adjuvant treatment; Aromatase inhibitors; Breast cancer; Endocrine therapy; Estrogen receptor; Hormonal treatment; Luteinizing hormone releasing hormone agonist; Postmenopausal; Premenopausal

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; BRCA1 PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERLOTINIB; ESTRADIOL; ESTRONE; EXEMESTANE; FLUOROURACIL; GEFITINIB; GONADORELIN AGONIST; GOSERELIN; LETROZOLE; LONAFARNIB; METHOTREXATE; PLACEBO; PROSTAGLANDIN RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAMOXIFEN CITRATE; TIPIFARNIB; TRASTUZUMAB; TRIPTORELIN; UNINDEXED DRUG; ZOLEDRONIC ACID;

ADJUVANT THERAPY; BONE NECROSIS; BREAST CANCER; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY CANCER; ENZYME INHIBITION; ESTRADIOL BLOOD LEVEL; ESTRONE BLOOD LEVEL; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; GENETIC CODE; HISTOPATHOLOGY; HOT FLUSH; HUMAN; METASTASIS POTENTIAL; MONOTHERAPY; MUSCULOSKELETAL DISEASE; MUTATIONAL ANALYSIS; OVARIECTOMY; OVERALL SURVIVAL; POSTMENOPAUSE; PREMENOPAUSE; PROGNOSIS; QUALITY OF LIFE; REVIEW; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; POSTMENOPAUSE; PREMENOPAUSE;

EID: 34948818179     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.9.1243     Document Type: Review

References (95)

1. Berry DA, Cronin KA, Pievritis SK et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N. Engl. J. Med. 353(17), 1784-1792 (2005).
2. Anderson WF, Chatterjee N, Ershler WB et al. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res. Treat. 76(1), 27-36 (2002).
3. Toft D, Gorski J. A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. Proc.. Natl Acad Sci. USA 55(6), 1574-1581 (1966).
4. Speirs V. Oestrogen receptor β in breast cancer: good, bad or still too early to tell? J. Pathol. 197(2), 143-147 (2002).
5. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25(1), 118-145 (2007).
6. Norris B, Chia S, Cheang M et al. Poor 10 year breast cancer specific survival and relapse free survival for HER2 positive T1NO tumors. Breast Cancer Res. Treat. 100(Suppl. 1), 2031 (2006).
7. Piccart-Gebhart MJ, Procter M. Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-posittve breast cancer. N. Engl. J. Med. 353 (16), 1659-1672 (2005).
8. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673-1684 (2005).
9. Slamon D, Eiermann W. Robert N et al. BCIRG 006: 2nd interim analysis Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Breast Cancer Res. Treat. l00(Suppl. 1), 52 (2006).
10. Joensuu. H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354(8), 809-820 (2006).
11. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406(6797), 747-752 (2000).
12. Sorlie T, Wang Y, Xiao C et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 7, 127 (2006).
13. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98(19), 10869-10874 (2001).
14. Kandel MJ, Stadler Z, Masciari S et al. Prevalence of BRCA1 mutations in triple negative breast cancer (BC). J. Clin. Oncol. 24, S18 (2006).
15. Halsted WS. The results of radical operation for the cure of carcinoma of the breast. Ann. Surg. 46, 1-19 (1907).
16. Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 2, 104-107 (1896).
17. Cole MP. The place of radiotherapy in the management of early breast cancer. A report of two clinical trials. Br. J. Surg. 51, 216-220 (1964).
18. Fisher B, Ravdin RG, Ausman RK et al. Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann. Surg. 168(3), 337-356 (1968).
19. Albain KS, Green SJ, Ravdin PM et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proc Am. Soc. Clin. Oncol. 21, A37 (2002) (Abstract 143).
20. Harris EE, Christensen VJ, Hwang WT et al. Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. J. Clin. Oncol. 23(1), 11-16 (2005).
21. Pierce LJ, Hutchins LF, Green SR et al. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J. Clin. Oncol. 23(1), 24-29 (2005).
22. Elledge RM, Allred DC. Clinical aspects of estrogen and progesterone receptors. In: Diseases of the Breast. Harris JR, Lippmann ME, Morrow M et al. (Eds). Lippincott Williams & Wilkins, PA, USA 603-617 (2004).
23. Dowsett M. Estrogen receptor: methodology matters. J. Clin. Oncol. 24(36), 5626-5628 (2006).
24. Nkoy FL, Hammond E, Rees W et al. Day of surgery affects estrogen receptor test results in women with breast cancer. Breast Cancer Res. Treat. 88(Suppl. 1), 5107 (2005).
25. Allred DC, Bryant J, Land S et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: findings from the NSABP Protocol B-24. Breast Cancer Res. Teat. 76(Suppl. 1), 30 (2002).
26. Harvey JM, Clark GM, Osborne CK et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 17(5), 1474-1481 (1999).
27. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472), 1687-1717 (2005).
28. Love RR, Duc NB, Allred DC et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J. Clin. Oncol. 20(10), 2559-2566 (2002).
29. Whelan EA. Sandler DP, McConnaughey DR et al. Menstrual and reproductive characteristics and age at natural menopause. Am. J. Epidemiol. 131(4), 625-632 (1990).
30. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J. Clin. Oncol. 14(5), 1718-1729 (1996).
31. Pagani O, O'Neill A, Castiglione M et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur. J. Cancer 34(5), 632-640 (1998).
32. Petrek JA, Naughton MJ, Case LD et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment a prospective study. J. Clin. Oncol. 24(7), 1045-1051 (2006).
33. Dowsett M, Richner J. Effects of cytotoxic chemotherapy on ovarian and adrenal steroidogenesis in pre-menopausal breast cancer patients. Oncology 48(3), 215-220 (1991).
34. Smith IE, Dowsett M, Yap YS et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J. Clin. Oncol. 24(16), 2444-2447 (2006).
35. Thompson EA Jr, Siiteri PK. The involvement of human placental microsomal cytochrome P450 in aromatization. J. Biol. Chem. 249(17). 5373-5378 (1974).
36. Lonning PE. Exemestane: a review of its clinical efficacy and safety. Breast 10(3), 198-208 (2001).
37. Haynes BP. Dowsett M, Miller WR et al. The pharmacology of letrozole. J. Steroid Biochem. Mol. Biol. 87(1), 35-45 (2003).
38. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351 (9114), 1451-1467 (1998).
39. Colleoni M, Rotmensz N, Peruzzotti G et al. Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann. Oncol. 17(10), 1497-1503 (2006).
40. Aebi S, Gelber S, Castiglione-Gerisch M et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 355(9218), 1869-1874 (2000).
41. Jonat W, Kaufmann M, Sauerbrei W et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association study J. Clin. Oncol. 20(24), 4628-4635 (2002).
42. Schmid P, Untch M, Wallwiener D et al. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-posittve, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast Cancer Study with Leuprorelin Acetate). Anticancer Res. 22(4), 2325-2332 (2002).
43. Castiglione-Gertsch M, O'Neill A, Price KN et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J. Natl Cancer Inst., 95(24), 1833-1846 (2003).
44. von Minckwitz G, Graf E, Geberth M et al. CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive brest cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93). Eur. J. Cancer 42(12). 1780-1788 (2006).
45. Boccardo F, Rubagotti A, Amoroso D et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J. Clin. Oncol. 18(14), 2718-2727 (2000).
46. Jakesz R, Hausmaninger H, Kubista E et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer - Austrian Breast and Colorectal Cancer Study Group Trial 5. J. Clin. Oncol. 20(24), 4621-4627 (2002).
47. Roche H. Kerbrat P, Bonneterre J et al. Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial. Ann. Oncol. 17(8), 1221-1227 (2006).
48. Arriagada R, Le MG, Spielmann M et al. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann. Oncol. 16 (3), 389-396 (2005).
49. Davidson NE, O'Neill AM, Vukov AM et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J. Clin. Oncol. 23(25), 5973-5982 (2005).
50. De Placido S, De Laurentiis M, De Lena M et al. A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. Br. J. Cancer 92(3), 467-474 (2005).
51. Baum M, Budzar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359(9324), 2131-2139 (2002).
52. Boccardo F, Rubagotti A. Puntoni M et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J. Clin. Oncol. 23(22), 5138-5147 (2005).
53. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366(9484), 455-462 (2005).
54. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349(19), 1793-1802 (2003).
55. Thurlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353(26), 2747-2757 (2005).
56. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350(11), 1081-1092 (2004).
57. Jakesz R, Samonigg H, Greil R et al. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG 6a). ASCO Meeting Abstracts 23 (Suppl. 16), 527 (2005).
58. Mamounas E, Jeong JH, Wickerham L et al. Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to treat analysis of NSABP B-33. Breast Cancer Res. Treat. 100(Suppl. 1), 49 (2006).
59. Buzdar AU, Guastalla JP, Nabholtz JM et al. Impact of chemotherapy regimens prior to endocrine therapy: results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial. Cancer 107(3). 472-480 (2006).
60. Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J. Clin. Oncol. 25(5), 486-492 (2007).
61. Coombes RC, Kilburn IS, Snowdon CF et al. Survival and safely of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369(9561), 559-570 (2007).
62. Boccardo F. Rubagotti A, Guglielmini P et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann. Oncol. 17 (Suppl. 7), 10-14 (2006).
63. Boccardo F, Rubagotti. A, Amoroso D et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. J. Clin. Oncol. 19(22), 4209-4215 (2001).
64. Boccardo F, Rubagotti A, Aldrighetti D et al. Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials. Cancer 109(6), 1060-1067 (2007).
65. Kaufmann M, Jonat W, Hilfrich J et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after 2 years of treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J. Clin. Oncol. 25(19), 1-7 (2007).
66. Jonat W. Gnant M, Boccardo F et al. Effectiveness of switching from adjuvant tamoxifen to anstrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol. 7(12), 991-996 (2006).
67. Ingle JN, Tu D, Pater JL et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res. Treat. 99(3), 295-300 (2006).
68. Garreau JR, Delamelena T, Walts D et al. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective. Am. J. Surg. 192 (4), 496-498 (2006).
69. Barron TI, Connolly R, Bennett K et al. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 109(5), 832-839 (2007).
70. Dowsett M, Allred DC. Relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial. Breast Cancer Res. Treat. 100(Suppl. 1), 48 (2006).
71. Stebbing J, Steams V, Davidson NE. Role of CYP2D6 testing in selection of endocrine therapy for breast cancer. Pharmacogenomics 8(1), 1-3 (2007).
72. Bernardi A, Zamagni C, Di Fabrio F et al. Randomized comparative study on estrogen suppression induced by 3 different aromatase inhibitors in postmenopausal patients with advanced breast cancer. Proc. Am. Soc. Clin. Oncol. 21, 217 (2002).
73. Dixon JM, Renshaw L, Young O et al. Letrozole suppresses plasma oestradiol (E2) levels more completely than anastrozole in postmenopausal women with breast cancer. ASCO Meeting Abstracts 24(Suppl. 18), 552 (2006).
74. Mayordomo J, Llombart A, Martin M et al. Randomized, multicenter, crossover Phase II trial to compare exemestane (E) vs. anastrozole (A) in postmenopausal patients (pt) with advanced breast cancer (ABC) and positive hormone receptors (HR). Final efficacy analysis of GEICAM 2001-03 study. ASCO Meeting Abstracts 24(Suppl. 18), 638 (2006).
75. Goldhirsch A, Coates AS, Gelber RD et al. First - select the target: better choice of adjuvant treatments for breast cancer patients. Ann. Oncol. 17(12), 1772-1776 (2006).
76. Carlson RW, Anderson BO, Burstein HJ et al. Invasive breast cancer, J. Natl Compr. Canc Netw. 5(3), 246-312 (2007).
77. Jonat W, Pritchard KI, Sainsbury R et al. Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient. J. Cancer Res. Clin. Oncol. 132(5), 275-286 (2006).
78. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J. Clin. Oncol. 23(3), 619-629 (2005).
79. Dowsett M, Stein RC, Coombes RC. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J. Steroid Biochem. Mol. Biol. 43(1-3), 155-159 (1992).
80. Forward DP, Cheung KL, Jackson L et al. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br. J. Cancer 90(3), 590-594 (2004).
81. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J. Clin. Oncol. 25(7). 820-828 (2007).
82. Body JJ. Breast cancer: bisphosphonate therapy for metastatic bone disease. Clin. Cancer Res. 12(20 Pt 2), 6258-6263 (2006).
83. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24(23), 3726-3734 (2006).
84. Ellis M. Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist 9(Suppl. 3), 20-26 (2004).
85. Mackey JR, Kaufman B, Clemens M et al. Thastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Breast Cancer Res. Treat. 100 (Suppl. 1), S5 (2006).
86. Stanway SJ, Delavault P. Purohit A et al. Steroid sulfatase: a new target for the endocrine therapy of breast cancer. Oncologist 12, 370-374 (2007).
87. Leary A, Dowsett M. Combination therapy with aromatase inhibitors: the next era of breast cancer treatment? Br. J. Cancer 95(6), 661-666 (2006).
88. Ejlertsen B, Mouridsen HT, Jensen MB et al. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. J. Clin. Oncol. 24(31), 4956-4962 (2006).
89. Baum M, Hackshaw A, Houghton J et al. Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study. Eur. J. Cancer 42(7), 895-904 (2006).
90. Rutqvist L. Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer: a randomised trial by the Cancer Research Campaign (C. R. C.) Breast Cancer Trials Group, the Stockholm Breast Cancer Study Group, the South-East Sweden Breast Cancer Group and the Gruppo Interdisciplinare Valutazione Interventi in Oncologia (G. I. V. I. O). Proc. Am. Soc. Clin. Oncol. 18(67), 251 (1999).
91. Robert NJ, Wang M, Cella D et al. Phase III comparison of tamoxifen versus tamoxifen with ovarian ablation in premenopausal women with axillary node-negative receptor-positive breast cancer ≤ 3 cm. Proc. Am. Son Clin. Oncol. 22, 16 (2003).
92. Soreide JA, Varhaug JE, Fjosne HE et al. Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study. Eur. J. Surg. Oncol. 28(5), 505-510 (2002).
93. The Adjuvant Breast Cancer Trials Collaborative Group. Ovarian ablation or suppression in premenopausal early breast cancer: Results from the International Adjuvant Breast Cancer Ovarian Ablation or Suppression Randomized Trial. J. Natl Cancer Inst. 99(7), 516-525 (2007).
94. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365(9453), 60-62 (2005).
95. Goss PE, Ingie JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl Cancer Inst. 97(17), 1262-1271 (2005).